Lots of regulatory news this week including one new molecular entity approval, an Advisory Committee thumbs-up for Novartis’s CAR-T program, a reversal for Amicus, and several new orphan drug designations. Here’s my summary of the top regulatory stories for this week: J&J subsidiary Janssen Biotech has secured approval from the FDA for its Tremfya (guselkumab)[…]